More Videos
SPECIAL REPORT
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Gold Retreats from Record High as Dollar Rebounds
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Wal-Mart Price Pressure Hurts China Workers: Report
- Fannie Mae to Tighten Lending Standards: Report
- Great Britain, No Longer That Great: Investor
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Euro Shares Record Biggest Drop in 7 Months
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
Whenever a politician, government agency or company puts out news late on a Friday chances are it probably isn't good or it's stuff they'd like to just slip under the door. That's when they like to dump stuff that will usually get less attention over a weekend news cycle when readers/viewers are distracted and/or catch reporters after their deadlines. Of course, they'll deny the ulterior motive, but it's a tried and true media relations practice.
So, should investors be all that surprised that Friday evening, May 1st,
Dendreon
[DNDN
Loading...
()
]
revealed that eight top execs and Directors unloaded a bunch of stock on April 29th and 30th, the two days following the release of the positive test results on the company's prostate cancer treatment?
CEO Dr. Mitchell Gold cashed in more than half a million shares. He's now a multi-millionaire. But the windfall is raising at least a few eyebrows. One shareholder emailed me saying, "This is kind of annoying if you're a (Dendreon) bull." However, these guys have probably been out of the money for years. I did a quick search and couldn't find any previous stock sales by Dr. Gold. And given the unpredictable, rocky history of Provenge, can you blame him/them for pocketing some cash after the huge run-up in the shares? I'm not making a judgment call there, I'm just raising the question.
Is it a signal about the fate of Provenge and the company? Based on their recent commentary, analysts would answer that with a unanimous "No." They all seem to think that FDA approval of the treatment is all but certain and that Dendreon's attractiveness as a partner or takeout target has gone, or will go, way up.
According to the company's proxy statement Dr. Gold received total compensation of $1.6 million last year. His package dropped slightly in 2007 to $1.23 million from $1.29 million in 2006. The statement also says Dr. Gold has (or had) as much as a 1.5% stake in the company. Wouldn't investors have more cause for concern if it turned out the CEO and others tried to thin their holdings (not that they could have) during that frenzied, two-minute cliff-drop last Tuesday before the data came out?
And speaking of that selloff, a follow-up to my Dendreon mailbag post last Friday that was filled with feedback on the stock action.
Pharma's Market Comments: |
Tony Masten wrote, "Just wanted to say thanks, because of your early reporting and keeping tabs on DNDN, I bought in at $4.55 for 2000 shares, at 20 I sold the May 20 calls for a very nice premium, before the actual news was released. It did not make me rich, but will be enough to pay off the rest of my mortgage! And be debt free."
I suspect Dr. Gold and the rest are debt-free now, too.
Clarification/Correction: A blogreader, only identified as Chris, was quick to point out that there were earlier Dendreon insider stock sales about two years ago during the first Provenge go-around. I have since found the so-called "Form 4"s under the "SEC Filings" tab on the Dendreon website, but they did not come up under the DNDN ticker symbol on the SEC's website.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes